In a nutshell This study is evaluating the safety and effectiveness of the D-KRd regimen (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in patients with multiple myeloma. The main outcome to be measured will be the number of patients who respond to treatment. This study is recruiting in Chicago, Illinois. The details Multiple myeloma (MM)...
Read MoreIn a nutshell This study is looking for patients with newly diagnosed multiple myeloma (MM) to try different treatment regimens. The main outcome that will be measured is the number of patients who do not experience cancer worsening after treatment. This trial is recruiting in Chicago, Illinois, United States. The details There are several...
Read More
In a nutshell This paper studied the effect of recommending bortezomib as the first drug to use for multiple myeloma in patients with poor kidney function. This study concluded that after bortezomib became the recommended drug, there was an increase in the number of patients who did not require dialysis. Some background Up to 50% of patients with...
Read MoreIn a nutshell This paper studied the effectiveness of daratumumab (Darzalex) in multiple myeloma patients who had received at least 1 previous treatment. This study concluded that daratumumab was more effective when used in combination with lenalidomide or bortezomib. Some background There is no standard treatment option for multiple myeloma that...
Read More
In a nutshell This paper reviewed the risk of heart disease in patients receiving treatment for multiple myeloma. Reducing the risk of heart disease is important in patients with multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells of blood. Treatment for multiple myeloma involves a group of drugs called proteasome...
Read More
In a nutshell This study aims to compare ixazomib plus dexamethasone versus pomalidomide plus dexamethasone on survival in participants with relapse and/or refractory multiple myeloma. The outcome to be measured is the duration of time until disease progresses (worsens). The details Multiple myeloma is a cancer of the plasma cells in the...
Read MoreIn a nutshell This study examined the impact of multi-drug resistant organisms in patients who had undergone stem cell treatment. The study concluded that patients colonized with multi-drug resistant organisms should be watched closely for infections after transplantation. Some background Stem cell transplantation is a treatment used in...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of a high-dose BeEAM chemotherapy as a first-line treatment for multiple myeloma. The primary outcome will be measured by the response to the treatment. The details BeEAM is a combination chemotherapy containing 4 different drugs (bendamustine, etoposide, cytarabine, and...
Read More
In a nutshell This early phase 1 clinical trial will test the safety and effectiveness of genetically engineered NY-ESO-1 specific (c259) T-cells cells with or without pembrolizumab (Keytruda) in treating relapsed or refractory (unresponsive to treatment) multiple myeloma. The details NY-ESO-1 is a protein found on many types of cancer cells...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of IRD, a combination therapy of ixazomib, lenalidomide, and dexamethasone, after stem cell transplantation, followed by ixazomib or lenalidomide as a maintenance therapy in treating multiple myeloma. The primary outcome will be measured by the disease improvement. The details...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of a combination of panobinostat (Farydak), gemcitabine (Gemzar), busulfan (Busulfex), and melphalan (Alkeran), and a stem cell transplant in treating multiple myeloma. The primary outcome will be measured by the time until the disease progresses. This trial is being conducted in...
Read More
In a nutshell This study examined the safety and effectiveness of ixazomib (Ninlaro) when added to the treatment of relapsed multiple myeloma. Researchers concluded that ixazomib was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background The addition of biologic drugs to standard treatment regimens for...
Read More
